CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-03 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −15,382 | $18.34 | $282K | 206,529 |
| 2024-01-03 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −24,583 | $19.05 | $468K | 181,946 |
| 2024-01-03 | Beskrovnaya Oxana Chief Scientific Officer | Sale 10b5-1 | −5,361 | $20.50 | $110K | 176,585 |
| 2024-01-03 | Beskrovnaya Oxana Chief Scientific Officer | Option exercise · Stock option (right to buy) 10b5-1 | −45,326 | 53,100 | ||
| 2024-01-03 | McNeill Jonathan Chief Business Officer | Option exercise 10b5-1 | +17,991 | $0.73 | $13K | 161,609 |
| 2024-01-03 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −7,691 | $18.34 | $141K | 153,918 |
| 2024-01-03 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −10,300 | $19.03 | $196K | 143,618 |
| 2024-01-03 | McNeill Jonathan Chief Business Officer | Option exercise · Stock option (right to buy) 10b5-1 | −17,991 | 50,537 | ||
| 2024-01-03 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise 10b5-1 | +13,000 | $1.03 | $13K | 137,228 |
| 2024-01-03 | Scalzo Richard William SVP, Head of Finance & Admin. | Sale 10b5-1 | −13,000 | $18.81 | $245K | 124,228 |
| 2024-01-03 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise · Stock option (right to buy) 10b5-1 | −13,000 | 25,740 | ||
| 2024-01-02 | McNeill Jonathan Chief Business Officer | Sale 10b5-1 | −11,900 | $13.10 | $156K | 143,618 |
| 2023-12-14 | Scalzo Richard William See Remarks | Sale 10b5-1 | −2,376 | $12.02 | $29K | 124,228 |
| 2023-12-12 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −978 | $10.55 | $10K | 169,096 |
| 2023-12-11 | Scalzo Richard William See Remarks | Sale | −1,380 | $10.72 | $15K | 126,604 |
| 2023-12-11 | McNeill Jonathan Chief Business Officer | Sale | −1,245 | $10.72 | $13K | 155,518 |
| 2023-12-11 | HIGH SUSANNA GATTI Chief Operating Officer | Sale | −1,616 | $10.72 | $17K | 187,882 |
| 2023-12-11 | Farwell Wildon Chief Medical Officer | Sale 10b5-1 | −1,688 | $10.72 | $18K | 170,074 |
| 2023-12-11 | Brumm Joshua T See Remarks | Sale | −7,585 | $10.72 | $81K | 584,971 |
| 2023-07-11 | McNeill Jonathan Chief Business Officer | Grant or award · Stock option (right to buy) | +35,000 | 35,000 |
Page 28 of 29 · 561 trades